A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms B-F1RST
- Sponsors Genentech
- 27 Sep 2017 Planned End Date changed from 9 Jun 2020 to 28 Jun 2019.
- 27 Sep 2017 Planned primary completion date changed from 9 Jun 2020 to 28 Jun 2019.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.